Doxorubicin resistance conferred by selective enhancement of intracellular glutathione peroxidase or superoxide dismutase content in human MCF-7 breast cancer cells.
To examine the role of doxorubicin-stimulated oxyradical formation in tumor cell killing, we introduced glutathione peroxidase (GSH Px) or superoxide dismutase (SOD) into MCF-7 cells by "scrape loading." Control cytoplasmic GSH Px and SOD levels increased from (mean +/- S.E.) 0.37 nmol/min/mg and 0.58 microgram SOD/mg, respectively, to 3.99 or 7.63 nmol/min/mg and 1.40 or 1.83 micrograms SOD/mg after treatment with either 150 or 300 units/ml of GSH Px or 20 or 40 mg/ml SOD. Resistance to doxorubicin was correlated with the level of GSH Px introduced into the MCF-7 cells; a one-hour exposure to 1.75 microM doxorubicin decreased the cloning efficiency of control cells loaded with medium alone to 34%, whereas doxorubicin-treated cells augmented with 150 or 300 units/ml of GSH Px had plating efficiencies of 56 or 86%, P less than 0.05. Introduction of SOD increased MCF-7 resistance to doxorubicin similarly. The heat-inactivated enzymes were not protective. Cells loaded with GSH Px were also resistant to the redox cycling anticancer quinone mitomycin C but not to the redox inactive analogs 5-iminodaunorubicin and mitoxantrone, suggesting that amplification of GSH Px or SOD levels can produce doxorubicin resistance in MCF-7 cells.
Doroshow
J H
JH
Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, California 91010.
Akman
S
S
Esworthy
S
S
Chu
F F
FF
Burke
T
T
D001943:Breast Neoplasms / Q000201:enzymology*; D004317:Doxorubicin / Q000494:pharmacology*; D004351:Drug Resistance / Q000502:physiology; D005609:Free Radicals; D005979:Glutathione Peroxidase / Q000378:metabolism*; D006801:Humans; D013482:Superoxide Dismutase / Q000378:metabolism*; D014407:Tumor Cells, Cultured
D005609:Free Radicals; D004317:Doxorubicin; D005979:Glutathione Peroxidase; D013482:Superoxide Dismutase